Effect of Hepatic Impairment on the Pharmacokinetics of Miricorilant: Results from a Phase 1, Open-Label, Adaptive-Design Study
Summary
- Miricorilant 600 mg was well tolerated in individuals with moderate or severe hepatic impairment and in matched-control healthy volunteers
- Hepatic impairment had minimal impact on the total systemic plasma area under the curve (AUC) of miricorilant
- These findings support future inclusion of individuals with compensated cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in the miricorilant clinical development program